Important Notices

On Aug. 7, 2026, Baxter Healthcare Corporation initiated a voluntary recall of selected lots of Myxredlin® (insulin human), Cardene IV® (nicardipine hydrochloride), Nexterone® (amiodarone HCl), and multiple injectable famotidine, clindamycin, dexmedetomidine, vasopressin, vancomycin, pantoprazole, and daptomycin products

On Aug. 4, 2026, Fresenius Kabi initiated a nationwide voluntary recall of one lot of Morphine Sulfate Injection

On July 30, 2026, GC Biopharma Corporation initiated a voluntary market withdrawal for three lots of Alyglo® (immune globulin intravenous, human-stwk) 10% Liquid.

On July 24, 2026, Baxter International Inc. initiated a voluntary recall of cefazolin in dextrose injection, USP, 2g/100mL (20mg/mL), single-dose infusion bag, 100mL.

On July 18, 2026, Unique Pharmaceutical Laboratories announced a voluntary consumer-level recall of four lots of cetirizine hydrochloride tablets 5mg

On June 4, 2026, Haleon announced a voluntary recall of its Gas X Extra Strength Softgels (simethicone) 125mg due to potential chemical contamination during packaging affecting select lots.

On May 27, 2025, Huons Co. Ltd. initiated voluntary recalls of lidocaine HCl injection and bupivacaine HCl in dextrose injection for all lots.

On May 26, 2026, Dexcom, Inc. initiated an urgent medical device correction involving select Dexcom G7® continuous glucose monitoring (CGM) sensors

On May 26, 2026, Insulet Corporation initiated a voluntary recall of specific lots of Omnipod® 5 pods, Omnipod DASH® pods, and Omnipod® Insulin Management System (Omnipod Eros) pods.

Dexcom, Inc. announced the planned discontinuation of the Dexcom G6 Continuous Glucose Monitoring (CGM) System effective July 1, 2026.